Replies to post #27258 on DNAprint Genomics (DNAG)

[geob]

Frog 96%>95%.....

we already have developed a product
called OVANOME_ in collaboration with the University of Florida and the
H. Lee Moffitt Cancer Center. OVANOME is a genomic-based diagnostic tool
for matching ovarian cancer patients with the most suitable form and
dose of chemotherapy. We're particularly concentrating on patients being
treated with the drug Taxol. In previous FDA trials, Taxol-Carboplatin
drug combination therapy demonstrated efficacy in only about 60% of
patients treated. Our OVANOME therapeutic response tests have yielded
encouraging results so far. They were 96% effective in distinguishing
Taxol-Carboplatin responders from non-responders.

96% EFFECTIVE

Maybe they are only 96% satisfied....

Hope this helps Frog---GEO

[geob]

FROG Lets look Back...

You said;...

Gabriel has specifically stated that Ovanome does not yet meet DNAP standards and is not yet ready for the FDA. That means, in no uncertain terms, that the product does not yet meet it's own design requirements.

If 95% is the design goal, perhaps they can't meet that level of accuracy, or perhaps they can meet it but not in a reliable and repeatable manner. Whatever the obstacle, the company has clearly stated it's status. It does not yet meet it's requirements and therefore is not ready for the FDA.

Sooooo FROG....

Lets be VERY CLEAR HERE...

They have a product that has a 96% success rate....

They, with the help of Moffit are under going a clinical study as we speak....

We can expect results and issuance to the FDA in or around 6 to 9 months....

DNAP's ONLY obstacle to date was the $1,000 per patient....

To perform the OVA test....

It seems that this obstacle has been overcome.....

They are ready....

VERY VERY READY---GEO